In Washington, D.C. on April 3, 2024, Vaxart, Inc., a clinical-stage biotechnology company based in South San Francisco, California, will be presenting at the World Vaccine Congress Washington 2024. Dr. Sean Tucker, the company’s Founder and Chief Scientific Officer, will be discussing the topic of “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination” during his presentation in Room 207A.
Vaxart is focused on developing oral recombinant vaccines using its proprietary delivery platform that allows for easy storage and shipping without refrigeration while eliminating the risk of needle-stick injuries. The company believes that its pill vaccine delivery platform is well-suited for delivering a range of vaccines, including oral versions of existing vaccines and new indications. Currently, Vaxart’s development programs include pill vaccines for protection against coronavirus, norovirus, and influenza as well as a therapeutic vaccine for human papillomavirus (HPV), the company’s first immune-oncology indication. Additionally, Vaxart has filed various patent applications domestically and internationally to cover its proprietary technology and creations related to oral vaccination using adenovirus and TLR3 agonists.
For media relations inquiries please contact Mark Herr at Vaxart Inc. For investor relations inquiries please reach out to Andrew Blazier.
